tallózása szerző szerint "Kopylov, U"

1-3 / 3

Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn’s disease: a systematic review and meta-analysis

Kopylov, U; Al-Taweel, T; Yaghoobi, M; Nauche, B; Bitton, A; Lakatos, Péter László; Ben-Horin, S; Afif, W; Seidman, EG (2014)
Discontinuation of Infliximab in Patients With Ulcerative Colitis is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study

Fiorino, G; Cortes, PN; Ellul, P; Felice, C; Karatzas, P; Silva, M; Lakatos, Péter László; Bossa, F; Ungar, B; Sebastian, S; Furfaro, F; Karmiris, K; Katsanos, KH; Muscat, M; Christodoulou, DK; Maconi, G; Kopylov, U; Magro, F; Mantzaris, GJ; Armuzzi, A; Boscà-Watts, MM; Ben-Horin, S; Bonovas, S; Danese, S (2016)
Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study.

Cesarini, M; Katsanos, K; Papamichael, K; Ellul, P; Lakatos, Péter László; Caprioli, F; Kopylov, U; Tsianos, E; Mantzaris, GJ; Ben-Horin, S; Danese, S; Fiorino, G (2014)

BACKGROUND: Subjects maintained on infliximab scheduled therapy for inflammatory bowel disease may require dose optimization due to secondary loss of response. There are limited data on infliximab dose optimization for ...

1-3 / 3

Keresés